Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 9	NOV 26	MARPAT enhanced with FSORT command
NEWS 10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 11	NOV 26	CHEMSAFE now available on STN Easy
NEWS 12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 13	DEC 01	ChemPort single article sales feature unavailable
NEWS 14	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 15	DEC 17	Fifty-one pharmaceutical ingredients added to PS

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:52:33 ON 19 DEC 2008

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:52:45 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 DEC 2008  HIGHEST RN 1086785-80-9
DICTIONARY FILE UPDATES:  18 DEC 2008  HIGHEST RN 1086785-80-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10590707scope.str
```





chain nodes :
18 22 23 24 25 26 27 28 29 30 31 32 33 34 37 38 39 40 42 43 44
45
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 46 47 49 50 51 52 53
54 55 56
chain bonds :
7-22 8-18 9-31 11-23 11-24 12-34 13-29 13-30 14-27 14-28 15-47 16-25
16-26 31-32 31-44 31-45 32-33 32-42 32-43 33-34 33-37 33-38 34-39 34-40
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16 46-47 46-52 47-49 49-50 50-51 50-53 51-52 51-56 53-54 54-55
55-56
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-22 8-9 8-18 9-10 11-12 11-16
11-23 11-24 12-13 12-34 13-14 13-29 13-30 14-15 14-27 14-28 15-16 15-47
16-25 16-26 31-44 31-45 32-42 32-43 33-37 33-38 34-39 34-40
exact bonds :
9-31 31-32 32-33 33-34
normalized bonds :
46-47 46-52 47-49 49-50 50-51 50-53 51-52 51-56 53-54 54-55 55-56
isolated ring systems :
containing 1 : 11 : 46 :

G1:H,NH2,Cb,Ak

G2:C,H,Ak

G3:C,N

<12/04/2007> Erich Leese

G4:C,H

G5:CH3,NH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 22:CLASS 23:CLASS
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 42:CLASS
43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 49:CLASS 50:CLASS 51:CLASS
52:CLASS 53:Atom 54:Atom 55:Atom 56:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,NH2,Cb,Ak
G2 C,H,Ak
G3 C,N
G4 C,H
G5 Me,NH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:53:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 74 TO ITERATE

100.0% PROCESSED 74 ITERATIONS 51 ANSWERS
SEARCH TIME: 00.00.01

L2 51 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 14:53:25 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 18 Dec 2008 (20081218/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2 full
L3 3 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:531773 CAPLUS
DOCUMENT NUMBER: 149:118596
TITLE: Biotransformation of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a novel 5-hydroxytryptamine (5-HT)1A agonist/5-HT3 antagonist, in human hepatic cytochrome P450 enzymes
AUTHOR(S): Minato, Kouichi; Suzuki, Ryota; Asagarasu, Akira; Matsui, Teruaki; Sato, Michitaka
CORPORATE SOURCE: Pharmacokinetics Research Department, ASKA Pharmaceutical Co., Ltd., Kawasaki, Japan
SOURCE: Drug Metabolism and Disposition (2008), 36(5), 831-840
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a novel 5-hydroxytryptamine (5-HT)1A agonist/5-HT3 antagonist, is currently under development for the treatment of irritable bowel syndrome. The objective of this investigation was to obtain information on the biotransformation of TZB-30878. This compound has quinazoline, piperazine, and quinoline rings. Metabolites of [quinazoline-2-14C]TZB-30878 were determined using radio high-performance liquid chromatog. on samples obtained after incubation with human hepatic microsomes. Eight metabolites were detected in the microsomal incubation mixture, and their structures were proposed by mass spectrometry techniques using TZB-30878 and two stable labeled TZB-30878 analogs, [quinoline-deuterium (D)6]TZB-30878 and [piperazin-D8]TZB-30878. Liquid chromatog./tandem mass spectrometry analyses suggested that the eight metabolites consisted of a cyclic metabolite (M6), four hydroxylated metabolites (M1, M2, M3, and M4) (three on quinoline ring and one on quinazoline ring), a deaminated metabolite (M5), and two metabolites (M7 and M8) that were presumably intermediates leading to the formation of the cyclic metabolite M6. Hydroxylation sites in the quinoline and quinazoline rings were predicted by electron d. calcns. and confirmed by comparison with authentic stds. To the best of our knowledge, N-deamination by microsomes leading to the formation of M5 appears to be novel. In addition, in vitro expts. in human liver microsomes with cytochrome P 450 (P 450)-specific inhibitors revealed that CYP3A4 was the major enzyme responsible for the metabolism of TZB-30878. Other P 450 enzymes, such as a CYP2D6, played a minor role in its metabolism

IT 864386-63-0
RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study)
(biotransformation of TZB-30878, novel 5-HT1A agonist/5-HT3 antagonist, in human hepatic cytochrome P 450 enzymes)

RN 864386-63-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-hydroxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



IT 864385-95-5, TZB-30878
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biotransformation of TZB-30878, novel 5-HT1A agonist/5-HT3 antagonist, in human hepatic cytochrome P 450 enzymes)
RN 864385-95-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:976866 CAPLUS
DOCUMENT NUMBER: 147:461966
TITLE: Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model
AUTHOR(S): Tamaoki, Satoru; Yamauchi, Yukinao; Nakano, Youichi; Sakano, Sayuri; Asagarasu, Akira; Sato, Michitaka
CORPORATE SOURCE: Pharmacological Research Department, ASKA Pharmaceutical Co., Ltd., Shimosakunobe, Takatsu-ku, Kawasaki, Japan
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 322(3), 1315-1323
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) is a novel compound with both 5-hydroxytryptamine (5-HT)1A agonism and 5-HT3 antagonism effects. We hypothesized that TZB-30878 might have benefits from these dual effects as a medication for diarrhea-predominant irritable bowel syndrome (d-IBS), and these studies were designed to confirm the pharmacol. properties of TZB-30878 and its efficacy in an IBS-like animal model. The binding assays demonstrated that [3H]TZB-30878 selectively binds to human 5-HT1A and 5-HT3 receptors, with Kd values of 0.68±0.03 and 8.90±1.73 nM, resp. Systemic administration of TZB-30878 inhibited 5-HT-induced bradycardia in a dose-dependent manner in rats. In behavioral assays TZB-30878 produced signs of 5-HT syndrome in rats. These results suggest that TZB-30878 has dual effects as a 5-HT1A receptor agonist and a 5-HT3 receptor antagonist. Finally, we evaluated the effects of TZB-30878 on wrap restraint stress-induced defecation in an IBS-like model in rats. TZB-30878 (1-10 mg/kg p.o.) normalized stress-induced defecation in a dose-dependent manner, whereas the 5-HT1A agonist tandospirone (30 and 100 mg/kg p.o.) and the 5-HT3 antagonist alosetron (1-10 mg/kg p.o.) did not show such effects. Furthermore, this efficacy of TZB-30878 was partly antagonized by a 5-HT1A antagonist, [O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635). These results suggest that 5-HT1A receptor agonism and 5-HT3 receptor antagonism contribute to the efficacy of TZB-30878 in the IBS-like model. The efficacy of TZB-30878 supports the concept that the presence of both actions, namely 5-HT1A receptor agonism and 5-HT3 receptor antagonism, could be an important mechanism in the treatment of d-IBS.

IT 864385-95-5
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. properties of TZB-30878, a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an exptl. IBS model)

RN 864385-95-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-

piperazinyl]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:979639 CAPLUS
DOCUMENT NUMBER: 143:286443
TITLE: Preparation of pyrimidine derivatives as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A
INVENTOR(S): Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato
PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005217320	A1	20050909	AU 2005-217320	20050225
CA 2557541	A1	20050909	CA 2005-2557541	20050225
EP 1724267	A1	20061122	EP 2005-719969	20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1922171	A	20070228	CN 2005-80005603	20050225
KR 2006127156	A	20061211	KR 2006-717068	20060824
US 20070197551	A1	20070823	US 2006-590707	20060825
PRIORITY APPLN. INFO.:			JP 2004-52040 A	20040226
			JP 2004-322858 A	20041105
			WO 2005-JP3691 W	20050225

OTHER SOURCE(S): MARPAT 143:286443
GI



I

II

AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, ploy-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2 steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT3 receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10-7 M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

IT 864386-62-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864386-62-9 CAPLUS

CN 4,6-Quinazolinedione, 3-amino-3,5,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



IT 864385-95-5P 864385-96-6P 864385-97-7P
864385-98-8P 864385-99-9P 864386-00-5P
864386-03-8P 864386-09-4P 864386-10-7P
864386-11-8P 864386-13-0P 864386-14-1P
864386-15-2P 864386-16-3P 864386-18-5P
864386-19-6P 864386-21-0P 864386-22-1P

864386-23-2P 864386-25-4P 864386-26-5P
864386-27-6P 864386-28-7P 864386-30-1P
864386-32-3P 864386-34-5P 864386-35-6P
864386-45-8P 864386-46-9P 864386-47-0P
864386-49-2P 864386-50-5P 864386-52-7P
864386-53-8P 864386-54-9P 864386-55-0P
864386-56-1P 864386-57-2P 864386-63-0P
864386-64-1P 864386-76-5P 864386-81-2P
864386-87-8P 864386-89-0P 864386-93-6P
864386-95-8P 864386-97-0P 864386-99-2P
864387-00-8P 864387-01-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864385-95-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864385-96-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864385-97-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864385-98-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864385-99-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(3-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-00-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(3,4-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-03-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(3,4-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-09-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-7-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-10-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6-bromo-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-11-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6,7,8-trimethoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-13-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-14-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-15-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-16-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(5-methoxy-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-18-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-19-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-21-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-22-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5-hydrazinyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-23-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-7-methyl-2-[4-[4-(2-quinolinyl)-1-

piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-25-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(5-methoxy-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-26-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-phenyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-27-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4,8-dimethyl-2-quinolinyl)-1-piperazinyl]butyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 864386-28-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(4,8-dimethyl-2-quinolinyl)-1-

piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-30-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-8-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-32-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-5,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-34-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-8-methoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-35-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6,7-dimethoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-45-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6-chloro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-46-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6-methoxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-47-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-7-(trifluoromethyl)- (CA INDEX NAME)



RN 864386-49-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-6-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-50-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-7-fluoro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-52-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-7-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-53-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-54-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6-ethyl-5,6,7,8-tetrahydro-2-[4-[4-(2-

quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-55-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-56-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-6-(1,1-dimethylethyl)-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-57-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-5,7,7-trimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-63-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-6-hydroxy-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-64-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-6-(trifluoromethyl)- (CA INDEX NAME)



RN 864386-76-5 CAPLUS
CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-81-2 CAPLUS
CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-87-8 CAPLUS
CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3,6-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-89-0 CAPLUS
CN 4(3H)-Quinazolinone, 5,6,7,8-tetrahydro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]pentyl]- (CA INDEX NAME)



RN 864386-93-6 CAPLUS
CN 4(3H)-Quinazolinone, 5-chloro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-95-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-97-0 CAPLUS
CN 4(3H)-Quinazolinone, 6,7-dimethoxy-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864386-99-2 CAPLUS
CN 4(3H)-Quinazolinone, 3,7-dimethyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864387-00-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



RN 864387-01-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-methyl-2-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     18.27     196.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -2.40      -2.40

FILE 'STNGUIDE' ENTERED AT 14:55:32 ON 19 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 12, 2008 (20081212/UP).

=> d his

     (FILE 'HOME' ENTERED AT 14:52:33 ON 19 DEC 2008)

     FILE 'REGISTRY' ENTERED AT 14:52:45 ON 19 DEC 2008
L1             STRUCTURE UPLOADED
L2          51 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:53:25 ON 19 DEC 2008
L3           3 S L2 FULL

     FILE 'STNGUIDE' ENTERED AT 14:55:32 ON 19 DEC 2008

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                      0.12     196.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -2.40

STN INTERNATIONAL LOGOFF AT 14:56:35 ON 19 DEC 2008
```